HomeCompareERYP vs PLD

ERYP vs PLD: Dividend Comparison 2026

ERYP yields 256.41% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERYP wins by $534.72M in total portfolio value
10 years
ERYP
ERYP
● Live price
256.41%
Share price
$0.78
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$541.22M
Annual income
$306,262,465.48
Full ERYP calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ERYP vs PLD

📍 ERYP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERYPPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERYP + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERYP pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERYP
Annual income on $10K today (after 15% tax)
$21,794.87/yr
After 10yr DRIP, annual income (after tax)
$260,323,095.66/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ERYP beats the other by $255,855,124.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERYP + PLD for your $10,000?

ERYP: 50%PLD: 50%
100% PLD50/50100% ERYP
Portfolio after 10yr
$273.86M
Annual income
$155,759,450.83/yr
Blended yield
56.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ERYP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERYP buys
0
PLD buys
0
No recent congressional trades found for ERYP or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERYPPLD
Forward yield256.41%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$541.22M$6.50M
Annual income after 10y$306,262,465.48$5,256,436.18
Total dividends collected$516.37M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ERYP vs PLD ($10,000, DRIP)

YearERYP PortfolioERYP Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$36,341$25,641.03$11,255$555.24+$25.1KERYP
2$125,971$87,086.09$13,062$1,018.59+$112.9KERYP
3$416,912$282,122.92$15,903$1,926.67+$401.0KERYP
4$1,318,722$872,626.36$20,839$3,823.32+$1.30MERYP
5$3,990,640$2,579,607.07$30,464$8,166.08+$3.96MERYP
6$11,565,551$7,295,566.53$52,054$19,457.30+$11.51MERYP
7$32,135,691$19,760,551.21$109,886$54,188.93+$32.03MERYP
8$85,699,274$51,314,084.97$304,030$186,451.18+$85.40MERYP
9$219,589,910$127,891,686.63$1,166,125$840,813.32+$218.42MERYP
10$541,223,669$306,262,465.48$6,504,190$5,256,436.18+$534.72MERYP

ERYP vs PLD: Complete Analysis 2026

ERYPStock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Full ERYP Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ERYP vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERYP vs SCHDERYP vs JEPIERYP vs OERYP vs KOERYP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.